Skip to content
PaperFren

Vaccination

What predicts full childhood immunization in Senegal

Mbengue MAS, Sarr M, Faye A, et al. · BMC public health · 2017

Open access · cc by · source: Europe PMC

Only 62.8% of Senegalese children 12–23 months were fully immunized; maternal education, wealth, and antenatal care strongly predicted coverage.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsVaccinationconcept

    Multiple studies in this library examine vaccination with empirical patient or population outcomes rather than opinion alone.

    Evidence for the claim as stated.

  • SupportsVaccinationconcept

    Complete coverage was 62.8%, below national (>80%) and international (>90%) goals; four antenatal visits associated with AOR 3.10 for complete immunization.

    Evidence for the claim as stated.

  • QualifiesVaccinationconcept

    In three West African DHS samples, full infant vaccination was about 15% and tracked care access more than child sex.

    Pooled 2019–20 DHS data for 5,368 children aged 0–12 months in The Gambia, Sierra Leone, and Liberia found full vaccination ~15.1% (males) and ~15.0% (females). Postnatal-care visits associated with higher odds (aOR 1.23); lower odds with father’s primary education (aOR 0.67), never watching TV (aOR 0.68), and only 1–3 antenatal visits (aOR 0.59).

    Scope note — Senegal 12–23-month complete-immunization estimate uses a later age window than 0–12-month ‘full’ status

    Limits the claim's scope: a different population, assay, or outcome.

  • SupportsVaccinationconcept

    Effect sizes and settings differ across vaccination studies — digital vs clinic, trial vs observational — so results should not be pooled casually.

    Evidence for the claim as stated.

  • SupportsVaccinationconcept

    Senegal’s 62.8% complete immunization among 12–23-month-olds is not the same claim as ~15% ‘full’ coverage among 0–12-month infants in The Gambia, Sierra Leone, and Liberia. Age windows, schedules, and ‘complete/full’ definitions differ, so the percentages should not be pooled as one West African coverage rate.

    Evidence for the claim as stated.

  • SupportsLogistic Regressionmethod

    In Senegal's 2010–2011 DHS, complete immunization among 2,199 children aged 12–23 months was 62.8%, below national (>80%) and international (>90%) goals. Four antenatal visits were associated with AOR 3.10 for complete immunization (card or maternal recall). That is an adjusted association in survey data, not a trial of an outreach programme, and recall can misclassify doses.

    Evidence for the claim as stated.

  • SupportsLogistic Regressionmethod

    The same odds-ratio language is asked to do two different jobs. Senegal's AOR 3.10 and the CDI 36% excess odds are observational associations after covariate adjustment. Text4Heart's AOR 2.55 is a randomised contrast that itself was gone by 6 months. Reading every AOR as if it were that trial overclaims the survey papers and understates how fragile a trial AOR can be once follow-up continues.

    Evidence for the claim as stated.

  • SupportsLogistic Regressionmethod

    Diagnostic papers optimise a cutoff, not an exposure odds ratio. CA125's PPV of 10.1% at a guideline threshold is a rare-disease problem; the diabetes score's NNS of 3–7 is a screening-workload problem that tracks prevalence, not AUC. Those operating-point numbers are not interchangeable with an immunization AOR of 3.10.

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

  • Scope difference — different assays, populations, or outcomes

    SupportsVaccination

    Effect sizes and settings differ across vaccination studies — digital vs clinic, trial vs observational — so results should not be pooled casually.

  • Scope difference — different assays, populations, or outcomes

    SupportsVaccination

    Senegal’s 62.8% complete immunization among 12–23-month-olds is not the same claim as ~15% ‘full’ coverage among 0–12-month infants in The Gambia, Sierra Leone, and Liberia. Age windows, schedules, and ‘complete/full’ definitions differ, so the percentages should not be pooled as one West African coverage rate.

  • Scope difference — different assays, populations, or outcomes

    The same odds-ratio language is asked to do two different jobs. Senegal's AOR 3.10 and the CDI 36% excess odds are observational associations after covariate adjustment. Text4Heart's AOR 2.55 is a randomised contrast that itself was gone by 6 months. Reading every AOR as if it were that trial overclaims the survey papers and understates how fragile a trial AOR can be once follow-up continues.

  • Scope difference — different assays, populations, or outcomes

    Diagnostic papers optimise a cutoff, not an exposure odds ratio. CA125's PPV of 10.1% at a guideline threshold is a rare-disease problem; the diabetes score's NNS of 3–7 is a screening-workload problem that tracks prevalence, not AUC. Those operating-point numbers are not interchangeable with an immunization AOR of 3.10.

History

When this study was placed

Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.

  1. 2026-09-17

    Placed as a scope qualifier on Vaccination

    Pooled 2019–20 DHS data for 5,368 children aged 0–12 months in The Gambia, Sierra Leone, and Liberia found full vaccination ~15.1% (males) and ~15.0% (females). Postnatal-care visits associated with higher odds (aOR 1.23); lower odds with father’s primary education (aOR 0.67), never watching TV (aOR 0.68), and only 1–3 antenatal visits (aOR 0.59).

  2. 2026-09-17

    Placed as supporting evidence on Vaccination

    Senegal’s 62.8% complete immunization among 12–23-month-olds is not the same claim as ~15% ‘full’ coverage among 0–12-month infants in The Gambia, Sierra Leone, and Liberia. Age windows, schedules, and ‘complete/full’ definitions differ, so the percentages should not be pooled as one West African coverage rate.

Study at a glance

Design
Cross-sectional — Secondary analysis of Senegal 2010–2011 DHS
N
N=2199 · Children aged 12–23 months
Population
Senegalese children aged 12–23 months in the Demographic and Health Survey
Outcome
Complete immunization coverage and maternal/household predictors

Structured fields used in claim comparison tables when every cited study has a complete layer.

Inspect source passages

What predicts full childhood immunization in Senegal

These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.

Complete immunization coverage was 62.8%.

The prevalence of complete immunization coverage among all children was 62.8% (Table ).

What maternal education pattern was noted?

More than half of women (68.7%) had no formal education and nearly 50% (43.8%) were classified as “poor/poorest” (Table ).
Read passages in the original paper

Key findings

Complete coverage was 62.8%, below national (>80%) and international (>90%) goals; four antenatal visits associated with AOR 3.10 for complete immunization.

Methodology

Secondary analysis of Senegal 2010–2011 DHS data for 2,199 children aged 12–23 months examined complete immunization (card or maternal recall) and maternal/household predictors.

Limitations

Causal effects of specific outreach programs, and recall-based vaccination histories can misclassify doses.

Related papers in this topic

Same topic cluster — not a recommendation engine.